Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-D immunoglobulin (Aegros)
- Development stage
- Preclinical
- Lead developer
- Aegros
- Modality
- Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
Anti-D Hyperimmune is a plasma-derived hyperimmune globulin being developed by Aegros for the prevention of Hemolytic Disease of the Fetus and Newborn (HDFN) in Rh-negative pregnant women. Manufactured using Aegros's proprietary HaemaFrac® technology—a novel electroseparation process that fractionates human plasma with high yield and purity—the product contains high concentrations of polyclonal IgG antibodies directed against the RhD antigen. When administered to Rh-negative mothers carrying an Rh-positive fetus, these antibodies bind to and clear fetal RhD-positive red blood cells from the maternal circulation, preventing maternal Rh sensitisation and subsequent immune-mediated destruction of fetal red blood cells in future pregnancies.
- Other names
- anti-D hyperimmuneanti-D hyperimmune globulinanti-D immunoglobulinhuman anti-D immunoglobulinRho(D) immune globulin
02
Targets
FCGR1A (High affinity immunoglobulin gamma fc receptor I)FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)ASGPR (Asialoglycoprotein Receptor 1)
Beyond the preview
Go deeper on anti-D immunoglobulin (Aegros).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-D immunoglobulin (Aegros).